Hasil Pencarian  ::  Simpan CSV :: Kembali

Hasil Pencarian

Ditemukan 42061 dokumen yang sesuai dengan query
cover
Sylvia S
Effectiveness comparison between insulin, sulfonylurea and sulfonylurea-biguanide combination on HbA1C and e-GFR level of type 2 diabetes mellitus patiens at Dr. Sitanala Hospital (article on The 1st International Conference on Pharmacy education and research network of ASEAN)
2015
MK-Pdf
UI - Makalah dan Kertas Kerja  Universitas Indonesia Library
cover
Sylvia
Perbandingan efektivitas insulin sulfonilurea kombinasi sulfonilurea biguanid terhadap nilai hba1c dan elfg pasien diabetes melitus tipe 2 di rsk dr sitanala tangerang = Effectiveness comparison between insulin sulfonylurea biguanide combination and sulfonylurea on hba1c and egfr level of type 2 diabetes patient in rsk dr siatanala tangerang
"[ABSTRAK
Penelitian mengenai efektivitas pengobatan diabetes melitus dan kaitannya
dengan pencegahan komplikasi masih menujukkan hasil yang beragam. Penelitian
ini bertujuan untuk membandingkan efektivitas hipoglikemik dan fungsi ginjal
dari sulfonilurea, kombinasi sulfonilurea dan biguanid serta injeksi insulin. Disain
penelitian adalah kohort retrospektif pada pasien diabetes melitus tipe 2 rawat
jalan yang mengkonsumsi obat yang sama selama empat bulan terakhir di RSK
Dr. Sitanala Tangerang. Penelitian ini dilaksanakan pada kurun waktu April-Juni
2015, dan sudah mendapatkan lulus kaji etik dari Komite Etik rumah sakit ini.
Subyek penelitian dibagi kedalam tiga kelompok yaitu yang menggunakan injeksi
insulin (n = 30), yang menggunakan obat sulfonilurea tunggal (n = 30), dan
kombinasi sulfonilurea dan biguanid (n = 45). Efektivitas hipoglikemik dilihat
dari nilai HbA1C pasien dan komplikasi nefropati diabetik dilihat dari nilai eLFG
yang dihitung dari angka serum kreatinin. Rerata usia keseluruhan pasien adalah
54,98±7,47, sebagian besar adalah wanita (72%) dan cenderung overweight
(rerata IMT 25,47±4,77). Ada perbedaan yang bermakna (p = 0,042 ) pada nilai
HbA1C pasien kelompok kombinasi sulfonilurea-biguanid (rerata HbA1C
7,28±0,09) dibandingkan dengan kelompok insulin (rerata HbA1C 8,10±0,09),
sementara dengan kelompok sulfonilurea tunggal tidak ada perbedaan yang
bermakna. Sedangkan nilai eLFG untuk setiap kelompok obat tidak ditemukan
perbedaan yang bermakna. Subyek yang memiliki riwayat diabetes melitus dalam
keluarga mempunyai peluang 4,512 kali (interval kepercayaan 95%, p = 0,010)
lebih besar dibandingkan dengan yang tidak memiliki riwayat diabetes dalam
keluarga untuk memiliki nilai HbA1C lebih dari 7%. Pasien dengan IMT >30
kg/m2 mempunyai peluang sebesar 21,631 (p = 0,012) dibandingkan pasien
dengan IMT < 18,5 kg/m2 untuk memiliki nilai HbA1C yang tidak terkontrol atau
diatas 7%. Pengobatan dengan kombinasi antidiabetik oral sulfonilurea dan
biguanid lebih efektif dalam menurunkan nilai HbA1C pasien DM tipe 2
dibandingkan dengan insulin atau sulfonilurea tunggal, dan tidak ada perubahan
bermakna dalam penurunan fungsi ginjal ABSTRACT Research on effectiveness of therapy on diabetes mellitus associated with
prevention of its complication still remain varied in results. The hypoglycemic
effectiveness and the kidney function were compared between sulfonylurea,
sulfonylurea and biguanide combination and insulin, with the retrospective cohort
study design, on patients that use those agents in last four months and came to
out-patient clinic of RSK Dr. Sitanala Tangerang. This research had the Ethical
Clearance from the Ethical Committee of this hospital. Subjects were classify into
three groups, i.e insulin group (n = 30), sulfonylurea group (n = 30) and
sulfonylurea and biguanide combination group (n = 45). Hypoglycemic
effectiveness is measured with the HbA1C level and diabetic nephrophaty with
the eGFR which calculated from the measured serum creatinin. Mean age of all
subjects was 54,98±7,47 (p=0,157), most were women (72%, p=0,235), and tend
to overweight (mean BMI is 25,49±4,84; p = 0,59). Mean HbA1C level from the
sulfonylurea-biguanide (7,28±0,09) group were significantly different (p = 0,042)
with those from the insulin group (8,10±0,09), and there was no significant
difference with the sulfonylurea group. There was no significant difference in
diabetic nephropathy between groups. Subject with diabetic family history has
4,512 times chance to have the HbA1C level > 7% compare to those without
diabetic family history. Subjects with BMI >30 kg/m2 have 21,631 times chance
to get the HbA1C >7% compare to subjects with BMI <18,5 kg/m2. Sulfonylurea
and biguanide combination was more effective compare to insulin or sulfonylurea
monotherapy on decreasing HbA1C level of type 2 DM patients, without
significant difference in effect of lowering kidney functionH;Research on effectiveness of therapy on diabetes mellitus associated with
prevention of its complication still remain varied in results. The hypoglycemic
effectiveness and the kidney function were compared between sulfonylurea,
sulfonylurea and biguanide combination and insulin, with the retrospective cohort
study design, on patients that use those agents in last four months and came to
out-patient clinic of RSK Dr. Sitanala Tangerang. This research had the Ethical
Clearance from the Ethical Committee of this hospital. Subjects were classify into
three groups, i.e insulin group (n = 30), sulfonylurea group (n = 30) and
sulfonylurea and biguanide combination group (n = 45). Hypoglycemic
effectiveness is measured with the HbA1C level and diabetic nephrophaty with
the eGFR which calculated from the measured serum creatinin. Mean age of all
subjects was 54,98±7,47 (p=0,157), most were women (72%, p=0,235), and tend
to overweight (mean BMI is 25,49±4,84; p = 0,59). Mean HbA1C level from the
sulfonylurea-biguanide (7,28±0,09) group were significantly different (p = 0,042)
with those from the insulin group (8,10±0,09), and there was no significant
difference with the sulfonylurea group. There was no significant difference in
diabetic nephropathy between groups. Subject with diabetic family history has
4,512 times chance to have the HbA1C level > 7% compare to those without
diabetic family history. Subjects with BMI >30 kg/m2 have 21,631 times chance
to get the HbA1C >7% compare to subjects with BMI <18,5 kg/m2. Sulfonylurea
and biguanide combination was more effective compare to insulin or sulfonylurea
monotherapy on decreasing HbA1C level of type 2 DM patients, without
significant difference in effect of lowering kidney functionH;Research on effectiveness of therapy on diabetes mellitus associated with
prevention of its complication still remain varied in results. The hypoglycemic
effectiveness and the kidney function were compared between sulfonylurea,
sulfonylurea and biguanide combination and insulin, with the retrospective cohort
study design, on patients that use those agents in last four months and came to
out-patient clinic of RSK Dr. Sitanala Tangerang. This research had the Ethical
Clearance from the Ethical Committee of this hospital. Subjects were classify into
three groups, i.e insulin group (n = 30), sulfonylurea group (n = 30) and
sulfonylurea and biguanide combination group (n = 45). Hypoglycemic
effectiveness is measured with the HbA1C level and diabetic nephrophaty with
the eGFR which calculated from the measured serum creatinin. Mean age of all
subjects was 54,98±7,47 (p=0,157), most were women (72%, p=0,235), and tend
to overweight (mean BMI is 25,49±4,84; p = 0,59). Mean HbA1C level from the
sulfonylurea-biguanide (7,28±0,09) group were significantly different (p = 0,042)
with those from the insulin group (8,10±0,09), and there was no significant
difference with the sulfonylurea group. There was no significant difference in
diabetic nephropathy between groups. Subject with diabetic family history has
4,512 times chance to have the HbA1C level > 7% compare to those without
diabetic family history. Subjects with BMI >30 kg/m2 have 21,631 times chance
to get the HbA1C >7% compare to subjects with BMI <18,5 kg/m2. Sulfonylurea
and biguanide combination was more effective compare to insulin or sulfonylurea
monotherapy on decreasing HbA1C level of type 2 DM patients, without
significant difference in effect of lowering kidney functionH;Research on effectiveness of therapy on diabetes mellitus associated with
prevention of its complication still remain varied in results. The hypoglycemic
effectiveness and the kidney function were compared between sulfonylurea,
sulfonylurea and biguanide combination and insulin, with the retrospective cohort
study design, on patients that use those agents in last four months and came to
out-patient clinic of RSK Dr. Sitanala Tangerang. This research had the Ethical
Clearance from the Ethical Committee of this hospital. Subjects were classify into
three groups, i.e insulin group (n = 30), sulfonylurea group (n = 30) and
sulfonylurea and biguanide combination group (n = 45). Hypoglycemic
effectiveness is measured with the HbA1C level and diabetic nephrophaty with
the eGFR which calculated from the measured serum creatinin. Mean age of all
subjects was 54,98±7,47 (p=0,157), most were women (72%, p=0,235), and tend
to overweight (mean BMI is 25,49±4,84; p = 0,59). Mean HbA1C level from the
sulfonylurea-biguanide (7,28±0,09) group were significantly different (p = 0,042)
with those from the insulin group (8,10±0,09), and there was no significant
difference with the sulfonylurea group. There was no significant difference in
diabetic nephropathy between groups. Subject with diabetic family history has
4,512 times chance to have the HbA1C level > 7% compare to those without
diabetic family history. Subjects with BMI >30 kg/m2 have 21,631 times chance
to get the HbA1C >7% compare to subjects with BMI <18,5 kg/m2. Sulfonylurea
and biguanide combination was more effective compare to insulin or sulfonylurea
monotherapy on decreasing HbA1C level of type 2 DM patients, without
significant difference in effect of lowering kidney functionH, Research on effectiveness of therapy on diabetes mellitus associated with
prevention of its complication still remain varied in results. The hypoglycemic
effectiveness and the kidney function were compared between sulfonylurea,
sulfonylurea and biguanide combination and insulin, with the retrospective cohort
study design, on patients that use those agents in last four months and came to
out-patient clinic of RSK Dr. Sitanala Tangerang. This research had the Ethical
Clearance from the Ethical Committee of this hospital. Subjects were classify into
three groups, i.e insulin group (n = 30), sulfonylurea group (n = 30) and
sulfonylurea and biguanide combination group (n = 45). Hypoglycemic
effectiveness is measured with the HbA1C level and diabetic nephrophaty with
the eGFR which calculated from the measured serum creatinin. Mean age of all
subjects was 54,98±7,47 (p=0,157), most were women (72%, p=0,235), and tend
to overweight (mean BMI is 25,49±4,84; p = 0,59). Mean HbA1C level from the
sulfonylurea-biguanide (7,28±0,09) group were significantly different (p = 0,042)
with those from the insulin group (8,10±0,09), and there was no significant
difference with the sulfonylurea group. There was no significant difference in
diabetic nephropathy between groups. Subject with diabetic family history has
4,512 times chance to have the HbA1C level > 7% compare to those without
diabetic family history. Subjects with BMI >30 kg/m2 have 21,631 times chance
to get the HbA1C >7% compare to subjects with BMI <18,5 kg/m2. Sulfonylurea
and biguanide combination was more effective compare to insulin or sulfonylurea
monotherapy on decreasing HbA1C level of type 2 DM patients, without
significant difference in effect of lowering kidney functionH]"
Fakultas Farmasi Universitas Indonesia, 2015
T42968
UI - Tesis Membership  Universitas Indonesia Library
cover
Rahmaningtyas Nurifahmi
Analysis of 8-iso-Prostglandin F2 and its correlation with estimated GFR in type 2 diabetes mellitius patiens consuming sulfonylurea and combination of biguanide-sulfyonylurea (article on The 1st International Conference on Pharmacy Education and Research Network of ASEAN)
Depok: Fakultas Farmasi Universitas Indonesia, 2015
MK-Pdf
UI - Makalah dan Kertas Kerja  Universitas Indonesia Library
cover
Endang Laelasari
Perbandingan efektivitas biaya antara terapi insulin, sulfonilurea dan sulfonilurea-biguanid pada pasien diabetes melitus tipe 2 RSK Dr. Sitanala Tangerang = Cost effectivness analysis of insulin sulfonylurea and sulfonylurea biguanid in type 2 diabetes mellitus in Dr. Sitanala leprosy hospital in Tangerang / Endang Laelasari
"ABSTRAK
Diabetes mellitus tipe 2 DMT2 adalah suatu kondisi ketika sel tubuh resisten terhadap insulin yang dihasilkan oleh sel ? pankreas. World Health Organization WHO memperkirakan prevalensi penderita DMT2 akan terus meningkat terutama di negara-negara berkembang termasuk Indonesia. Pengobatan diabetes jangka panjang, pola peresepan yang beragam dan perbedaan harga insulin dibandingkan sulfonilurea dan biaguanid menyebabkan perbedaan biaya yang dikeluarkan untuk terapi. Penelitian merupakan analitik deskriptif dengan desain cross sectional.Penelitian dilakukan untuk mengetahui efektivitas pengobatan dan efisiensi biaya antidiabetes pada pasien DMT2 rawat jalan di RSK Dr. Sitanala Tangerang pada periode April 2015 - Juni 2015 yang mengkomsumsi obat yang sama selama 4 bulan terakhir. Subjek penelitian dibagi menjadi tiga kelompok yaitu yang menggunakan insulin n=29 , yang menggunakan obat sulfonilurea n=29 dan yang menggunakan kombinasi sulfonilura-biguanid n=39 .Efektivitas pengobatan dilihat dari nilai HbA1c pasien dan analisis antidiabetes dari segi efektivitas pengobatan dan biaya dilakukan dengan menggunakan Cost Effectiveness Analysis CEA . Hasil penelitian menunjukkan bahwa pasien DMT2 berjenis kelamin perempuan lebih banyak dibandingkan pasien laki-laki yaitu 68 orang 65,96 dengan rata-rata usia pasien DMT2 yaitu 50-59 tahun. Efektivitas tertinggi dihasilkan oleh kombinasi sulfonilurea-biguanid yaitu 7,48 1,89. Nilai ACER Average cost effectiveness ratio kelompok insulin adalah Rp. 40.866, kelompok sulfonilurea adalah Rp. 1.369 dan kelompok kombinasi sulfonilurea-biguanid adalah Rp. 2.621. Nilai ICER incremental cost effectiveness ratio untuk terapi sulfonilurea-biguanid terhadap terapi sulfonilurea adalah Rp. 16.194. Berdasarkan analisis yang dilakukan, terapi kombinasi sulfonilurea-biguanid lebih cost effective dibandingkan terapi insulin ataupun terapi sulfonilurea tunggal.
ABSTRACT
Type 2 diabetes mellitus T2DM is a condition when the body cells are resistant to insulin produced by the pancreas cells. World Health Organization WHO estimates that the prevalence of type 2 diabetes will continue to increase, especially in developing countries, including Indonesia. Long term diabetes treatment, prescribing pattern varied and the price difference compared to sulfonylurea insulin and biaguanid cause differences in costs incurred for treatment. The research is descriptive analytic with cross sectional design.The study was conducted to examine the effectiveness and cost efficiency antidiabetic treatment in patients with type 2 diabetes outpatient Dr. Sitanala Leprosy Hospital in Tangerang in the period April 2015 June 2015 were consuming the same drug during the last 4 months. Subjects were divided into three groups who use insulin n 29 , which uses a sulfonylurea drug n 29 and those using sulfonilura biguanide combination n 39 .The effectiveness of treatment views of HbA1c values of patients and analysis of antidiabetic terms of the effectiveness of treatment and the cost is done by using the Cost Effectiveness Analysis CEA . Results showed that patients with type 2 diabetes were female more than male patients ie 68 65.96 with an average age of patients with type 2 diabetes that is 50 59 years. The highest effectiveness generated by the combination of sulfonylurea biguanide is 7.48 1.89. Value ACER Average cost effectiveness ratio insulin group is Rp. 40 866, sulfonylurea group is Rp. 1369 and the combination of sulfonylurea biguanide group is Rp. 2,621. Value ICER incremental cost effectiveness ratio for the treatment of sulfonylurea biguanide to sulfonylurea therapy is Rp. 16 194. Based on the analysis performed, sulfonylurea biguanide combination therapy is more cost effective than sulfonylurea insulin therapy or single therapy."
2017
T47346
UI - Tesis Membership  Universitas Indonesia Library
cover
Wulandari
Analysis of urinary hydrogen peroxide and its correlation with estimated GFR in type 2 diabetes mellitus patients consuming sulfonylurea and combination of biguanide-sulfonylurea (article on The 1st International Conference on Pharmacy Education and Research Network of ASEAN, December 2-4, 2015)
"Renal dysfunction which frequently occurs in type 2 diabetes mellitus patients caused by oxidative stress. The effectiveness of the type 2 diabetes mellitus treatment to renal dysfunction is unknown. This study compare and analyze the correlation between urinary hydrogen peroxide which is a product of oxidative stress and estimated glomerular filtration rate (eGFR) in the treatment groups of sulfonylurea and combination biguanide-sulfonylurea. This study used a retrospective cohort study design with 50 sampels that was taken in Dr. Sitanala Tangerang hospital with total sampling technique. Estimated GFR value obtained based on serum creatinine values were measured using a kinetic Jaffe method, while the urinary hydrogen peroxide using FOX 1 (Ferrous ion Oxidation Xylenol Orange1). Value of urinary hydrogen peroxide in the two treatment groups did not have significant difference (p = 0.69), while the eGFR value of two groups did not have significant differences with the Cockroft Gault is p = 0.884; MDRD p = 0.886; and CKDEPI p = 0.490. Correlation analysis of urinary hydrogen peroxide and eGFR based on the MDRD equation and CKDEPI generate significant positive correlation (r = 0.326; p = 0.021) and (r = 0.282; p = 0.047). There is no antioxidant activity in the treatment groups. Urinary hydrogen peroxide may play a role in the pathophysiologic significance of diabetic nephropathy."
Depok: Fakultas Farmasi Universitas Indonesia, 2015
MK-Pdf
UI - Makalah dan Kertas Kerja  Universitas Indonesia Library
cover
Rafidah Saraswati
Perbandingan Efektivitas Terapi Kombinasi Metformin-Sulfonilurea dengan Metformin-Akarbose pada Pasien Diabetes Melitus Tipe 2 = Comparison the Effectiveness of Metformin-Sulfonylurea with Metformin-Acarbose Combination Therapy in Type 2 Diabetes Mellitus Patients
"ABSTRAK
Metformin-sulfonilurea dan metformin-akarbose adalah kombinasi terapi yang memiliki mekanisme kerja yang menguntungkan juga diperuntukan dalam pemilihan pengobatan diabetes melitus tipe 2. Review ini bertujuan untuk merangkum perkembangan studi terkini mengenai efektivitas kedua kombinasi obat tersebut. Pencarian literatur artikel penelitian dilakukan secara sistematis dengan melakukan pencarian data melalui Summons Search LIB UI dan didapatkan artikel dari beberapa database yaitu ScienceDirect, ProQuest, Springerlink, dan PubMed. Artikel penelitian yang digunakan dalam review adalah literatur primer yang diterbitkan selama 10 tahun terakhir. Terdapat 6 artikel penelitian yang memenuhi kriteria inklusi. Masing-masing penelitian membahas efek pengobatan dan efektivitas terapi kombinasi dari nilai HbA1c, kejadian hipoglikemia, mean amplitude of glycemic excursions, tingkat stress oksidatif, dan manfaat terapi kombinasi pada risiko kejadian kardiovaskular. Terjadi penurunan nilai HbA1c pada setiap terapi kombinasi dan tidak ada perbedaan nilai yang signifikan pada keduanya, tetapi dari kombinasi metformin-sulfonilurea lebih besar dalam menurunkan nilai HbA1c. Namun, pada terapi kombinasi metformin-akarbose dilaporkan dapat menurunkan nilai dari mean amplitude of glycemic excursions (MAGE), berat badan, dan serum trigliserida, serta terjadi peningkatan serum adiponektin tanpa efek signifikan pada stres oksidatif. Kombinasi metformin-akarbose juga lebih cenderung memiliki manfaat yang lebih baik terutama pada pasien diabetes yang memiliki komplikasi pada kardiovaskular dan tidak meningkatkan risiko terjadinya hipoglikemia.
ABSTRACT
Metformin-sulfonylurea and metformin-acarbose are combination therapy that has a beneficial mechanism action for treating type 2 DM. This review aims to summarize the recent studies regarding the effectiveness of the two drug combinations. The literature search was carried out through Summons Search LIB UI. The research articles used in the review are the primary literature published over the past 10 years. There were 6 research articles that met the inclusion criteria. Each study discussed the effectiveness of combination therapy from HbA1c values, incidence of hypoglycemia, mean amplitude of glycemic excursions, levels of oxidative stress, and benefits of combination therapy on the risk of cardiovascular events. There was a decrease in the value of HbA1c in each combination therapy and there was no significant difference in the value, but the combination of metformin-sulfonylurea was greater in reducing the HbA1c value. However, metformin-acarbose combination therapy was reported to reduce the mean amplitude of glycemic excursions, body weight, and serum triglycerides, as well as increased the serum adiponectin without a significant effect on oxidative stress. The metformin-acarbose combination is more likely to have a better benefit in diabetic patients who have cardiovascular complications and also not increasing the risk of developing hypoglycemia."
Depok: Fakultas Farmasi Universitas Indonesia, 2020
S-pdf
UI - Skripsi Membership  Universitas Indonesia Library
cover
Fitriyani
Analisis Efektivitas-Biaya Terapi Kombinasi Metformin-Insulin dan Metformin-Sulfonilurea pada Pasien Rawat Jalan dengan Diabetes Mellitus Tipe 2 di RSUPN Dr. Cipto Mangunkusumo = Cost-Effectiveness Analysis of Metformin-Insulin and Metformin-Sulfonylurea Combination Therapy in Outpatients with Type 2 Diabetes Mellitus at RSUPN Dr. Cipto Mangunkusumo.
"ABSTRAK
Diabetes mellitus (DM) tipe 2 diketahui sebagai salah satu masalah kesehatan yang memberikan beban ekonomi yang cukup besar pada sistem pelayanan kesehatan di seluruh dunia. Bervariasinya penggunaan terapi obat akan mengakibatkan adanya perbedaan dalam efektivitas dan biaya terapi, sehingga perlu dilakukan analisis efektivitas-biaya. Tujuan dari penelitian ini adalah menganalisis efektivitas-biaya terapi kombinasi metformin-insulin dan metformin-sulfonilurea pada pasien rawat jalan dengan DM tipe 2. Penelitian ini menggunakan desain studi kohort, pengambilan data dilakukan secara retrospektif di RSUPN Dr. Cipto Mangunkusumo menggunakan rekam medik pasien rawat jalan dengan DM tipe 2 dari tahun 2016-2019 dan data billing rumah sakit. Efektivitas terapi (∆HbA1c) dan biaya medis langsung antara kedua kelompok dibandingkan. ∆HbA1c antara kelompok metformin-insulin dan kelompok metformin-sulfonilurea tidak memiliki perbedaan yang bermakna secara statistik (rerata perbedaan 0,123%; p=0,608). Sedangkan median biaya medis langsung kelompok metformin-insulin lebih tinggi dibandingkan kelompok metformin-sulfonilurea (p < 0,001). Hasil analisis efektivitas-biaya menunjukkan bahwa terapi kombinasi metformin-sulfonilurea lebih cost-effective dibandingkan kombinasi metformin-insulin.
ABSTRACT
Type 2 diabetes mellitus (DM) has been recognized as one of the health problems that imposes economic costs to health care systems around the world. Variation of drug therapy will result in differences in effectiveness and cost of therapy, thus cost-effectiveness analysis has been regarded paramount. The purpose of this study is to analyze the cost-effectiveness of metformin-insulin and metformin-sulfonylurea combination therapy in outpatients with type 2 DM. This cohort study was conducted retrospectively at RSUPN Dr. Cipto Mangunkusumo using medical records of outpatients with type 2 DM from 2016-2019 and hospital billing. The effectiveness of therapy (∆HbA1c) and direct medical costs between the two groups were compared. ∆HbA1c between the metformin-insulin group and the metformin-sulfonylurea group did not have statistically significant differences (mean difference 0,123%; p=0,608). While the median of direct medical costs of the metformin-insulin group was higher than metformin-sulfonylurea group (p < 0.001). The results of the cost-effectiveness analysis showed that the combination therapy of metformin-sulfonylurea was more cost-effective compared to the combination of metformin-insulin."
2019
T55097
UI - Tesis Membership  Universitas Indonesia Library
cover
Maria Irene Hendrata
Hubungan temperamen dengan pengendalian kadar HBA1C pada penyandang diabetes melitus tipe 2 di Poliklinik Metabolik Endokrin RSCM = Relationship between temperament and HBA1C level control in type 2 diabetes mellitus patients in Cipto Mangunkusumo hospital RSCM metabolism endocrine polyclinic / Maria Irene Hendrata
"Latar Belakang: Prevalensi Diabetes Melitus (DM) tipe 2 cenderung meningkat di seluruh dunia dan keteraturan pengobatan masih menjadi masalah hingga saat ini. Penelitian terdahulu menemukan bahwa terdapat hubungan antara temperamen dengan kontrol glukosa namun belum banyak penelitian yang membahas hal ini. Penelitian ini bertujuan mengetahui hubungan antara temperamen dengan terkontrol atau tidak terkontrolnya DM tipe 2.
Metode: Penelitian ini adalah penelitian analitik potong lintang. Pengambilan sampel dilakukan dengan consecutive sampling pada 110 penyandang DM tipe 2 di Poliklinik Metabolik Endokrin RSCM selama bulan Agustus-Desember 2015. Responden dikelompokkan menjadi penyandang DM terkontrol atau DM tidak terkontrol berdasarkan hasil laboratorium HbA1c terakhir. Responden mengisi kuesioner Modified-Temperament and Character Inventory versi bahasa Indonesia.
Hasil: Hasil penelitian ini menunjukkan bahwa skor temperamen harm avoidance, novelty seeking, dan reward dependence tidak berhubungan bermakna dengan terkontrol atau tidak terkontrolnya DM tipe 2.
Simpulan: Tidak ada hubungan bermakna antara temperamen dengan pengendalian kadar HbA1c pada penyandang DM tipe 2.
Background: Prevalence on type 2 Diabetes Mellitus (DM) tend to increase across the world and regulating treatment still being one of the matters to be discussed until recently. Previous research had found that there are correlations between temperament with glucose control but with limited study on that area. This research aim to qualify the relationship between temperament to controllable or uncontrollable type 2 DM.
Method: This research is a cross sectional sampling method. Sampling conducted with consecutive sampling on 110 respondents with type 2 DM in RSCM Metabolism Endocrine Polyclinic, sampling was done between August to December 2015. Respondents are grouped to two different groups which is controllable DM and uncontrollable DM based on last HbA1c laboratory results. Respondents were requested to fill up Modified-Temperament and Character Inventory questionnaire in Bahasa Indonesia.
Results: Result on this research indicates that temperament score in harm avoidance, novelty seeking, and reward dependence are unrelated with whether Type 2 DM being controllable or uncontrollable.
Conclusion: Absent of significant relation between temperament and HbA1c level control in type 2 DM patients."
Depok: Fakultas Kedokteran Universitas Indonesia, 2015
T-Pdf
UI - Tesis Membership  Universitas Indonesia Library
cover
Nurul Aisyah
Hubungan antibodi anti-p53 dengan HbA1c, insulin, dan IGF-1 pada pasien diabetes melitus tipe 2 yang menerima terapi metformin dan non-metformin = The correlation between anti-p53 antibody, HbA1c, IGF-1, and insulin in metformin and non-metformin-treated type 2 diabetes mellitus patients
"Beberapa studi epidemiologi maupun studi metaanalisis menunjukkan faktor seperti jenis kelamin dan usia, obesitas, dan resistensi insulin, pada diabetes mellitus tipe 2 memiliki hubungan dengan risiko terjadinya kanker. Hiperinsulinemia dapat mempengaruhi risiko kanker tidak hanya melalui efek mitogenik langsung dari insulin tetapi juga secara tidak langsung melalui peningkatan produksi IGF-1. Metformin yang merupakan terapi lini pertama untuk pasien diabetes melitus tipe 2 telah dikaitkan dengan risiko berkurangnya berbagai sel kanker. Penelitian ini merupakan penelitian cross-sectional yang bertujuan untuk membandingkan dan menganalisis hubungan antibodi anti-p53 dengan beberapa penanda metabolik HbA1c, insulin, dan IGF-1 pada pasien diabetes melitus yang menerima terapi antidiabetes metformin n=47 , non-metformin n=31 , dan subjek sehat n=16 di Puskesmas Pasar Minggu. Sampel yang digunakan adalah serum darah yang kemudian diuji menggunakan metode ELISA untuk menganalisis antibodi anti-p53, IGF-1, dan Insulin. Nilai antibodi anti-p53, yaitu 0,26 0,06 dan pada kelompok metformin tunggal/kombinasi dan 0,24 0,08 pada kelompok non-metformin. Nilai pada kedua kelompok memiliki perbedaan yang bermakna p< 0,001 jika dibandingkan dengan subjek sehat. Terdapat korelasi negatif menengah antara antibodi anti-p53 dengan HbA1c r = -0,407; p= 0,023 dan dengan IGF-1 r = - 0,571; p = 0,021 pada kelompok non-metformin. Tidak terdapat hubungan yang bermakna antara antibodi anti-p53 dengan kadar insulin pada ketiga kelompok.
Either epidemiological studies or meta analysis has shown that several factors such as gender, age, obesity, and insulin resistance are related to cancer incidents. Hyperinsulinemia affect cancer progression not only trough insulin mitogenic activities but also trough inducing IGF 1 production. Metformin as a first line therapy for patients with type 2 diabetes mellites has been associated with a reduced risk of various cancer cells. Aside from its insulin sensitizer mechanism, several studies showed other mechanism related to cancer treatment. This cross sectional study compares and analyzes the correlation between effect of antidiabetic treatment in the group of metformin combination n 47 and non metformin n 31 against anti p53 antibody and their relation to HbA1c, IGF 1, and insulin in type 2 diabetes mellitus patients in Pasar Minggu Primary Health Center. Patient rsquo s blood serum was collected then analyzed with ELISA kit to measure the value of anti p53 antibody, IGF 1, and insulin. The average of anti p53 antibody were 0.26 0.06 and 0.24 0.08 in metformin combination group and non metformin group, respectively. There was a statistically significant difference anti p53 antibody level between the two groups against age and sex match 16 apparently healthy subjects."
Depok: Fakultas Farmasi Universitas Indonesia, 2017
S68867
UI - Skripsi Membership  Universitas Indonesia Library
cover
Clarasintha Nindyatami
Analisis efektivitas-biaya terapi kombinasi metformin- akarbose dan metformin-sulfonilurea pada pasien diabetes mellitus tipe 2 di RSPAD Gatot Soebroto = Cost effectiveness analysis of metformin acarbose and metformin sulfonylurea combination therapy in diabetes mellitus type 2 patients in RSPAD Gatot Soebroto
"Diabetes mellitus tipe 2 merupakan penyakit dengan beban biaya tinggi dan dapat memberi efek negatif terhadap kualitas hidup penderitanya. Diabetes merupakan salah satu penyakit yang banyak dijumpai pada pasien RSPAD Gatot Soebroto. RSPAD Gatot Soebroto merupakan pemberi pelayanan kesehatan tingkat tiga yang menjadi rujukan tertinggi bagi Tentara Nasional Indonesia TNI Angkatan Darat dan masyarakat. Terapi diabetes mellitus tipe 2 memiliki beragam pola terapi kombinasi. Terapi yang beragam akan memberikan efektivitas dan biaya yang berbeda pula. Penelitian ini dilakukan terhadap dua jenis terapi kombinasi, yaitu metformin-akarbose dan metformin-sulfonilurea. Penelitian ini memberikan gambaran terapi kombinasi yang memiliki efektivitas-biaya lebih baik dalam segi tingkat pencapaian target HbA1C.
Diabetes mellitus type 2 is a high cost disease and has a negative effect on patients rsquo quality of life. Diabetes mellitus type 2 is one of the main diseases found in RSPAD Gatot Soebrotos outpatients. RSPAD Gatot Soebroto is a tertiary health care provider which is the highest medical care referral for the Indonesian Army and society. Diabetes mellitus type 2 therapy has various combination therapy patterns. Different therapy will give different effectiveness and cost result. This study was done for two combination therapies, metformin acarbose and metformin sulfonylurea. This study gives an insight on which combination therapy is more cost effective based on the target HbA1C."
Depok: Fakultas Farmasi Universitas Indonesia, 2018
S-Pdf
UI - Skripsi Membership  Universitas Indonesia Library
<<   1 2 3 4 5 6 7 8 9 10   >>